Navigation Links
Micromet to Present at Two Upcoming Investor Conferences
Date:2/7/2008

BETHESDA, Md., Feb. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at two upcoming investor conferences; one sponsored by the Biotechnology Industry Organization (BIO) and the other by Roth Capital Partners.

Dr. Itin will present at the 2008 BIO CEO and Investor Conference in New York, on Wednesday, February 13, 2008 at 2:00 pm Eastern Time (8:00 pm Central European Time). An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com, as well as a replay and download of the presentation slides following the event.

Dr. Itin will also present at the Roth Capital Partners 2008 OC Growth Stock Conference in Dana Point California, on Tuesday, February 19, 2008 at 9:30 am Pacific Time.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline developed using the BiTE(R) antibody technology platform , is being developed in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second cl
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
6. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Genelabs Technologies to Present at the BIO CEO & Investor Conference
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)...  Personal Genome Diagnostics Inc. (PGDx), today announced ... expertise in genomic analysis of defined cancer subtypes ... Blueprint Medicines.  PGDx is an innovator in conducting ... tumors, and Blueprint Medicines is an expert in ... defined patient population. "This collaboration brings ...
(Date:5/21/2013)... 2013 Revolutionary Science, the manufacturer of ... announced today that they have expanded their colony counter ... IncuCount, IntelliCount, InCount and ImpressCount. These affordable colony ... useful in food microbiology and pharmaceutical manufacturing. , The ... A bright white enclosure with jet black accents ...
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the ... of pixantrone for the treatment of diffuse large B-cell ... Drug Administration,s (the "FDA") Division of Hematologic Products (the ... the PIX-R or PIX 306 trial, will compare a ...
... thigh bones that enable them to support huge loads whilst ... the journal Proceedings of the Royal Society B . ... of new materials based on thigh bone geometry. A ... collected thigh bone samples from British museum collections and zoos, ...
... , BOULDER, Colo.Physicists at the National,Institute of ... in which microwaves communicate with,a vibrating mechanical ... before in,similar experiments. The microscopic,apparatus is a ... control the,motion of a relatively large object ...
Cached Biology Technology:FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5Study of 90 animals' thigh bones reveals how they can efficiently carry loads 2Study of 90 animals' thigh bones reveals how they can efficiently carry loads 3NIST electromechanical circuit sets record beating microscopic 'drum' 2NIST electromechanical circuit sets record beating microscopic 'drum' 3
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... the world,s largest scientific society, invites news media ... September 8-12, 2013, in Indianapolis, Ind. It will ... at area hotels. , With more than 7,100 ... from astronomy to zoology ― the meeting ... rich assortment of spot news and feature possibilities. ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2
... a protein implicated in Alzheimer's disease, researchers at UT ... gene responsible for producing the specific protein ?called amyloid-beta ... and greatly reduce the protein's build-up in the brain. ... of Alzheimer's disease. , "The whole point of the ...
... researchers at Duke's Pratt School of Engineering have imaged ... demonstration showed that the probes could give surgeons a ... are performed through tiny "keyhole" incisions. , If the ... lead to more precise and safer endoscopic surgeries, said ...
... University of York have launched a new research project which ... Researchers from the University's Department of Biology are heading the ... cells for use in the repair of bone defects and ... in the UK and across Europe, as well as academics ...
Cached Biology News:DNA gene vaccine protects against harmful protein of Alzheimer's disease 2Rare Tibetan antelope listed as endangered 2Rare Tibetan antelope listed as endangered 3Bones from blood: Scientists aim to break new ground on fractures 2
Reacts with methylated DNA from plants and vertebrates...
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: